Results 191 to 200 of about 839,337 (241)

Longitudinal evaluation of anti-SARS-CoV-2 neutralizing antibody levels in 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccinated kidney transplant population: 18-month follow-up. [PDF]

open access: yesIJID Reg
Karunathilake KRP   +9 more
europepmc   +1 more source

mRNA-1273 and Ad26.COV2.S Vaccines Protect Against the B.1.621 Variant of SARS-CoV-2

open access: green, 2022
Tamarand L. Darling   +16 more
openalex   +1 more source

POS-975 SEROLOGIC RESPONSE TO THE mRNA-1273 and BNT162b2 COVID-19 VACCINES IN DIALYSIS PATIENTS

open access: gold, 2022
Kevin Yau   +4 more
openalex   +1 more source

Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines. [PDF]

open access: yesCell Rep
Bangaru S   +19 more
europepmc   +1 more source

mRNA-1273/ravulizumab [PDF]

open access: yesReactions Weekly, 2021
openaire   +1 more source

mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron

open access: yesCell, 2022
M. Gagne   +76 more
semanticscholar   +1 more source

Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination [PDF]

open access: gold
Salma Younes   +14 more
openalex   +1 more source

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

open access: yesLancet. Infectious Diseases (Print), 2022
A. Munro   +308 more
semanticscholar   +1 more source

Safety and Immunogenicity of an mRNA-1273 Booster in Children. [PDF]

open access: yesClin Infect Dis
Berthaud V   +26 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy